- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Insurance Increases Diagnosis and Control of Chronic Conditions
People with insurance have significantly higher probabilities of being diagnosed for diabetes, hypercholesterolemia, and hypertension than people without insurance.
People with insurance have significantly higher probabilities of being diagnosed for diabetes, hypercholesterolemia, and hypertension than people without insurance, according to findings published in Health Affairs.
In addition, people with insurance who were diagnosed had significantly lower hemoglobin A1c, total cholesterol, and systolic blood pressure than uninsured individuals. THe investigators analyzed data from 1999 to 2012 from the National Health and Nutrition Examination Survey to evalute the relationship between health insurance and the diagnosis and management of diabetes, hypercholesterolemia, and hypertension.
Given insurance coverage expansion under the Affordable Care Act (ACA), the authors found that the health law coul have significant effects on chronic disease identification and management.
"Evidence on expected health impacts and health services use is urgently needed by policy makers as they plan for the likely effects of the ACA's full implementation," the authors wrote.
They found that for people with insurance the probability of diagosis was 13.5% higher for diabetes and hypercholesterolemia and 8.8% higher for hypertension. The investigators determined that if the number of nonelderly Americans without health insurance was reduced by half, there would be 313,000 fewer cases of undiagnosed diabetes, 811,000 fewer cases of undiagnosed hypercholesterolemia, and 485,000 undiagnosed cases of hypertension.
If all nonelderly Americans had health insurance, there would be 3.1 million more people diagnosed with one of these 3 chronic conditions, and 1.3 million fewer with uncontrolled cases.
"Our findings suggest that the ACA could have significant effects on the identificaiton and management of chronic disease," the authors concluded. "However, more attention is needed to the potential short-term and long-term impolications of these health changes for the demand for health care services and health care spending on chronic disease."
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
